Blog
RSS FeedPosted by Michael Wonder on 26 Jun 2022
Highlights from the 20-23 June 2022 CHMP meeting
24 June 2022 - EMA’s CHMP recommended nine medicines for approval at its June 2022 meeting. ...
Posted by Michael Wonder on 23 Jun 2022
NICE opts to reject Acorda’s MS drug Fampyra
22 June 2022 - NICE has announced its decision to reject Fampyra – also known as fampridine – for use ...
Posted by Michael Wonder on 22 Jun 2022
MSAC publishes agenda for October 2022 ESC meeting
22 June 2022 - The MSAC Secretariat has published a list of applications scheduled to be considered by the ESC on ...
Posted by Michael Wonder on 22 Jun 2022
Slow release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis
21 June 2022 - The Department of Health and Social Care has asked NICE to produce guidance on using slow-release ...
Posted by Michael Wonder on 21 Jun 2022
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma
21 June 2022 - The Department of Health and Social Care has asked NICE to produce guidance on using tebentafusp ...
Posted by Michael Wonder on 20 Jun 2022
EMA publishes agenda for 20-23 June 2022 CHMP meeting
20 June 2022 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 20 Jun 2022
Zeposia is included in the high-cost protection with limitation
17 June 2022 - Zeposia (ozanimod) is included in the high-cost protection with limited subsidy from 17 June 2022. ...
Posted by Michael Wonder on 20 Jun 2022
Givlaari is included in the high-cost protection with limitation
17 June 2022 - Givlaari (givosiran) is included in the high-cost protection with limited subsidy to reduce attacks in patients with ...
Posted by Michael Wonder on 19 Jun 2022
EU HTA regulation: international preparatory meeting in Cologne
17 June 2022 - At the invitation of IQWiG, 41 envoys from European HTA organisations and two from the EU ...
Posted by Michael Wonder on 19 Jun 2022
Current issues in health technology assessment of cancer therapies: a survey of stakeholders and opinion leaders in Australia
17 June 2022 - The aim of this study was to find ways of bridging the gap in opinions concerning health ...
Posted by Michael Wonder on 17 Jun 2022
NICE recommends new targeted treatment for early breast cancer
16 June 2022 - NICE has provisionally approved a new treatment for early breast cancer that it says will benefit ...
Posted by Michael Wonder on 17 Jun 2022
Outcomes of the May 2022 PBAC intracycle meeting
17 June 2022 - The outcomes from the May 2022 PBAC meeting are now available. ...
Posted by Michael Wonder on 17 Jun 2022
Public consultation: draft 2022-23 cost recovery implementation statement for listing medicines on the PBS and designated vaccines on the NIP
17 June 2022 - Consultation on the content of the draft 2022-23 Cost Recovery Implementation Statement (CRIS) for listing medicines ...
Posted by Michael Wonder on 16 Jun 2022
Core network partners announced for CADTH’s post-market drug evaluation network
10 June 2022 - CADTH is pleased to announce the four successful core network partners of its inaugural post-market drug ...
Posted by Michael Wonder on 16 Jun 2022
New treatment to increase the chances of a successful kidney transplant recommended by NICE
16 June 2022 - A new treatment that increases the chance of a successful kidney transplant has been recommended by ...